



Appointment of two new independent directors to EOS imaging's Board of Directors

Paris, 2 July 2012 - EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, has announced the appointment of Michael Dormer and Eric Beard to its Board of Directors for a period of three years.

Michael Dormer (age 61) has a more than 30 year experience in medical devices and more specifically orthopaedics, in which he has held a number of high-ranking positions. He joined Johnson & Johnson in 1976 before moving to De Puy in 1992, where he served as President and oversaw the company's IPO in 1996. Following the acquisition of De Puy by Johnson & Johnson, he became Chairman of the Medical Devices and Diagnostics division at Johnson & Johnson. He is currently a director of Jenavalve, Endosense and Neoss.

Eric Beard (age 61) joined Baxter Healthcare in 1975, where he pursued an international career, principally in North America, Asia Pacific and Europe. He held various positions of increasing importance in finance and later was in charge of Baxter's renal products in various countries and regions. In 1999, he assumed global responsibility for the dialysis business as President. In 2001, he was appointed President of Baxter EMEA. He joined Sorin Group in 2003 as International President in charge of worldwide sales and marketing. He is currently Chairman of Cellnovo.

Marie Meynadier, Chief Executive Officer of EOS imaging, comments: *"We are extremely pleased to welcome two outstanding professionals to our Board of Directors. Their knowledge of the sector and complementary experiences will make a very significant contribution to our Board of Directors. We will also be able to capitalise on their very strong international dimension as we step up our rate of expansion into the United States and Asia."*

**About EOS imaging**

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EC). Thanks to an installed base of 47 sites and more than 150,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 57 people including an R&D team of 21 engineers and recorded consolidated revenue of €6.9 million in 2011. The Group's head office is based in Paris, with a subsidiary in the United States at Cambridge, Massachusetts, in Montreal (Canada) and in Germany.

Further information about EOS imaging can be found at the following site: www.eos-imaging.com

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



Next press release: revenue for the first half of 2012, 25 July 2012 (after market).

Contacts :

Anne Renevot
CFO
Tel.: +33 (0)1 55 25 61 24
investors@eos-imaging.com

NewCap.
Financial communication and investor relations
Sophie Boulila / Pierre Laurent
Tel.: +33(0)1 44 71 94 91 – eosimaging@newcap.fr

ALIZE RP
Press Relations
Caroline Carmagnol / Anne-Sophie Cosquéric
Tel : +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59
caroline@alizerp.com / anne-sophie@alizerp.com